NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis

Enanta Pharmaceuticals, Inc. (ENTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ENTA

$11.31

−$0.36 (−3.08%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ENTA with… →

ENTA Key Statistics

As of Oct 21, 2026
Trading
Open
$11.64
Previous Close
$11.67
Day's Range
11.24–11.85
52-Week Range
10.20–17.15
Volume
166.83K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$329.41M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.42
Financials (FY)
Revenue (FY)
$65.32M−3.42%
Net Income (FY)
−$81.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
−96.89%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
29.13M
1-Year Return
+2.72%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
233.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ENTA closed at $11.31, +2.72% over 1 year.

Enanta Pharmaceuticals, Inc. (ENTA) has a market capitalization of $329.41M.

In fiscal 2025, ENTA reported revenue of $65.32M.

ENTA Stock Return by Calendar Year

Enanta Pharmaceuticals, Inc. (ENTA) 10-year return: what $10,000 became

1 year
$10,000 $10,272
+2.72%
5 years
$10,000 $1,568
−84.32%
10 years
$10,000 $4,598
−54.02%

If you had invested $10,000 in Enanta Pharmaceuticals, Inc. (ENTA) 10 years ago, at the close on October 21, 2016, it would have been worth $4,598 at the close on October 21, 2026: −54.02% in total, −7.48% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.28%
2025+174.26%
2024−38.89%
2023−79.77%
2022−37.79%
2021+77.62%
2020−31.85%
2019−12.78%
2018+20.71%
2017+75.16%
2016 (partial year)+54.31%

As of October 21, 2026.

ENTA Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$65.32M−$81.89M−125.4%
2024$67.64M−$116.05M−171.6%
2023$79.20M−$133.82M−169.0%
2022$86.16M−$121.76M−141.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$65.32M—−$85.35M−$81.89M−125.4%
2024$67.64M—−$121.69M−$116.05M−171.6%
2023$79.20M—−$137.21M−$133.82M−169.0%
2022$86.16M—−$123.84M−$121.76M−141.3%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

ENTA Valuation vs Biotechnology Median

Median of 608 stocks
MetricENTABiotechnology medianvs median
P/S ratio5.0513.3062% below
Profit margin−96.89%−38.31%58.6 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Enanta Pharmaceuticals, Inc. (ENTA) at $329.41M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 120.

The most recent close on file for ENTA is $11.31, dated October 21, 2026. That is −$0.36 (−3.08%) against the previous close. The 52-week range on file runs from $10.20 to $17.15. The latest close sits 10.88% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $65.32M. Against the prior fiscal year total of $67.64M, that is a change of −3.42%. The same year closed with a net loss of $81.89M. The reported profit margin is −96.89%. That is 58.6 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −2.42.

Across the 4 fiscal years on file, revenue moves from $86.16M in 2022 to $65.32M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 5.05. On price-to-sales that is 62.04% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +2.72%. Measured over 10 years, that is −7.48% a year compounded. Beta against the wider market is reported at 0.96. Annualized volatility over the trailing 10 years is 60.94%.

Growth & Income

No dividend is on file for ENTA.

Across the complete calendar years on file, 2025 returned +174.26% and 2023 returned −79.77%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −28.28% year to date.

Peer Comparison

Enanta Pharmaceuticals, Inc. (ENTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Enanta Pharmaceuticals, Inc. ENTA $329.41M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Enanta Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Visit website →